NSG 552 Psychopharmacology Exams 1-3 Prep Document |
2026/2027 Edition | 200 Verified Questions - 167 Questions
with Answers
NSG 552 Psychopharmacology Exams 1-3 2026-167 QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document for NSG 552 Psychopharmacology covers all three
exams with 200 actual questions and verified answers, each accompanied by detailed rationales.
Designed for nursing students, it ensures mastery of psychopharmacological principles, drug
classifications, and clinical applications. The content is aligned with the 2026/2027 curriculum and
reflects the latest evidence-based practices. Guaranteeing a pass, this resource is essential for exam
success.
Key Features:
Foundations of Psychopharmacology: Neurotransmission, receptor pharmacology, pharmacokinetics,
pharmacodynamics
Antidepressants: SSRIs, SNRIs, TCAs, MAOIs, atypical antidepressants, and their clinical use
Mood Stabilizers: Lithium, anticonvulsants (valproate, lamotrigine), and their monitoring parameters
Antipsychotics: First-generation (typical) and second-generation (atypical) agents, including clozapine
management
Anxiolytics and Sedative-Hypnotics: Benzodiazepines, buspirone, z-drugs, and melatonin receptor agonists
Stimulants and ADHD Medications: Methylphenidate, amphetamines, atomoxetine, and alpha-2 agonists
Cognitive Enhancers: Cholinesterase inhibitors and NMDA receptor antagonists for dementia
Substance Use Disorders: Pharmacotherapy for alcohol, opioid, and nicotine dependence
Special Populations: Pregnancy, geriatrics, pediatrics, and hepatic/renal impairment considerations
Drug Interactions and Adverse Effects: CYP450 interactions, QT prolongation, serotonin syndrome, and
neuroleptic malignant syndrome
Patient Education and Adherence: Strategies for promoting medication adherence and managing side effects
Clinical Decision-Making: Case-based scenarios integrating assessment, diagnosis, and pharmacologic
management
Evidence-Based Practice: Current guidelines and research in psychopharmacology
Legal and Ethical Considerations: Prescriptive authority, informed consent, and monitoring requirements
Exam Strategies: Test-taking tips and rationales for multiple-choice questions
Comprehensive Review: Integration of all topics across Exams 1, 2, and 3
Updates for 2026:
- Updated to reflect 2026/2027 DSM-5-TR and APA guidelines
- Incorporated latest FDA approvals and black box warnings
- Enhanced rationales with evidence-based references
- Added new case studies and clinical scenarios
- Revised to align with current WU curriculum and exam blueprint
Abstract:
This exam preparation document for NSG 552 Psychopharmacology provides a rigorous compilation of 200 actual
questions from Exams 1-3, with verified answers and detailed rationales. The content spans foundational
neuroscience, major drug classes, and clinical applications, ensuring comprehensive coverage of the course
syllabus. Each question is designed to test critical thinking and application of psychopharmacological principles in
Page 1
,patient care. The rationales explain correct and incorrect options, reinforcing learning and clarifying
misconceptions. Updated for the 2026/2027 academic year, this resource aligns with the latest evidence-based
practice and professional standards. It is an indispensable tool for nursing students aiming to excel in their
examinations and future clinical practice.
Keywords:
Psychopharmacology, NSG 552, Exam prep, Verified answers, Rationales, Nursing, 2026/2027, Guaranteed pass
Answer Format:
Each question is followed by the correct answer, a detailed rationale explaining why it is correct, and concise
explanations for why the other options are incorrect. Rationales include clinical pearls, drug mechanisms, and
relevant guidelines to enhance understanding and retention.
Compliance Checklist:
Aligned with 2026/2027 WU NSG 552 course objectives
Includes 200 actual exam questions with verified answers
Rationales provided for every answer option
Updated to reflect current psychopharmacology guidelines
Suitable for self-assessment and exam review
Content Area Overview:
Content Area Questions Key Topics Weight
Foundations of 1-20 Neurotransmission, receptor pharmacology, 10%
Psychopharmacology pharmacokinetics, pharmacodynamics
Antidepressants 21-50 SSRIs, SNRIs, TCAs, MAOIs, atypical 15%
antidepressants
Mood Stabilizers 51-70 Lithium, valproate, lamotrigine, monitoring 10%
Antipsychotics 71-100 First-generation, second-generation, 15%
clozapine, side effects
Anxiolytics and 101-120 Benzodiazepines, buspirone, z-drugs, 10%
Sedative-Hypnotics melatonin agonists
Stimulants and ADHD 121-140 Methylphenidate, amphetamines, 10%
Medications atomoxetine, alpha-2 agonists
Cognitive Enhancers 141-150 Cholinesterase inhibitors, NMDA 5%
antagonists
Substance Use Disorders 151-165 Alcohol, opioid, nicotine pharmacotherapy 8%
Special Populations 166-175 Pregnancy, geriatrics, pediatrics, organ 5%
impairment
Drug Interactions and Adverse 176-185 CYP450, QT prolongation, serotonin 5%
Effects syndrome, NMS
Patient Education and Adherence 186-190 Adherence strategies, side effect 2%
management
Clinical Decision-Making 191-195 Case-based scenarios, assessment, 3%
management
Evidence-Based Practice and 196-200 Guidelines, prescriptive authority, ethics 2%
Legal/Ethical
Page 2
,Q1. A patient with treatment-resistant depression is being considered for ketamine.
Which pharmacodynamic property best explains its rapid antidepressant effect?
A. Antagonism at the NMDA receptor with subsequent AMPA receptor upregulation
B. Inhibition of monoamine oxidase A and B
C. Blockade of serotonin reuptake and dual 5-HT2 antagonism
D. Allosteric modulation of GABA-A receptors
Correct Answer: A. Antagonism at the NMDA receptor with subsequent AMPA
receptor upregulation
Rationale: Ketamine's antidepressant effect is primarily attributed to noncompetitive
NMDA receptor antagonism, leading to enhanced AMPA receptor signaling and
downstream synaptogenesis. MAO inhibition, SSRI-like effects, and GABA modulation do
not produce the rapid, robust response characteristic of ketamine.
Why Wrong:
B - MAO inhibition increases monoamines but lacks the rapid synaptogenic
mechanisms of ketamine.
C - Serotonin reuptake blockade and 5-HT2 antagonism describe agents like
trazodone, which do not act within hours.
D - GABA-A modulation produces anxiolytic effects but is not associated with rapid
antidepressant efficacy.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 15
Q2. Which cytochrome P450 enzyme is primarily responsible for the metabolism of
aripiprazole, and what is the clinical implication for a patient with a poor CYP2D6
metabolizer phenotype?
A. CYP3A4; the drug will be metabolized faster, requiring dose escalation
B. CYP2D6; the drug will accumulate, increasing risk of extrapyramidal symptoms
C. CYP1A2; the drug will be less effective due to rapid clearance
D. CYP2C19; the drug will have reduced efficacy and require adjunctive therapy
Correct Answer: B. CYP2D6; the drug will accumulate, increasing risk of
extrapyramidal symptoms
Rationale: Aripiprazole is a substrate of CYP2D6 and CYP3A4. In poor metabolizers of
CYP2D6, aripiprazole exposure is increased, raising the risk of dose-dependent adverse
effects such as EPS and akathisia. Dose adjustment is recommended.
Why Wrong:
A - CYP3A4 is a minor pathway; poor CYP2D6 status causes accumulation, not faster
metabolism.
C - CYP1A2 is not a major pathway for aripiprazole.
D - CYP2C19 is not significantly involved in aripiprazole metabolism.
Page 3
, Reference: Stahl, S.M. (2026). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 6
Q3. A patient on fluoxetine is prescribed tramadol. What is the most serious potential
interaction and the mechanism?
A. Increased seizure risk due to lowered threshold
B. Serotonin syndrome due to excessive serotonin agonism
C. Hypertensive crisis due to monoamine oxidase inhibition
D. QT prolongation leading to torsades de pointes
Correct Answer: B. Serotonin syndrome due to excessive serotonin agonism
Rationale: Fluoxetine inhibits CYP2D6, which is needed to convert tramadol to its active
metabolite, but the combination also increases serotonin levels via both drugs, leading to
serotonin syndrome. Seizure risk is less specific and not the most serious interaction.
Why Wrong:
A - Both drugs can lower seizure threshold, but the more dangerous interaction is
serotonin syndrome.
C - Fluoxetine is not an MAOI; hypertensive crisis is more typical of MAOI-tyramine
interactions.
D - QT prolongation is possible but less specific to this combination.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 28
Q4. Which of the following best describes the mechanism of action of valproate in
mood stabilization?
A. Selective inhibition of voltage-gated sodium channels
B. Increase in brain GABA levels through inhibition of GABA transaminase
C. Blockade of dopamine D2 receptors in the mesolimbic pathway
D. Antagonism of glutamate at AMPA receptors
Correct Answer: B. Increase in brain GABA levels through inhibition of GABA
transaminase
Rationale: Valproate elevates GABA levels by inhibiting GABA transaminase and
enhancing GABA synthesis, which contributes to its antimanic and anticonvulsant effects.
Sodium channel blockade is more characteristic of carbamazepine and lamotrigine.
Why Wrong:
A - Sodium channel blockade is a mechanism of lamotrigine and carbamazepine, not
valproate.
C - D2 blockade is typical of antipsychotics.
D - AMPA antagonism is not a primary mechanism of valproate.
Reference: Stahl, S.M. (2026). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 11
Page 4
2026/2027 Edition | 200 Verified Questions - 167 Questions
with Answers
NSG 552 Psychopharmacology Exams 1-3 2026-167 QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document for NSG 552 Psychopharmacology covers all three
exams with 200 actual questions and verified answers, each accompanied by detailed rationales.
Designed for nursing students, it ensures mastery of psychopharmacological principles, drug
classifications, and clinical applications. The content is aligned with the 2026/2027 curriculum and
reflects the latest evidence-based practices. Guaranteeing a pass, this resource is essential for exam
success.
Key Features:
Foundations of Psychopharmacology: Neurotransmission, receptor pharmacology, pharmacokinetics,
pharmacodynamics
Antidepressants: SSRIs, SNRIs, TCAs, MAOIs, atypical antidepressants, and their clinical use
Mood Stabilizers: Lithium, anticonvulsants (valproate, lamotrigine), and their monitoring parameters
Antipsychotics: First-generation (typical) and second-generation (atypical) agents, including clozapine
management
Anxiolytics and Sedative-Hypnotics: Benzodiazepines, buspirone, z-drugs, and melatonin receptor agonists
Stimulants and ADHD Medications: Methylphenidate, amphetamines, atomoxetine, and alpha-2 agonists
Cognitive Enhancers: Cholinesterase inhibitors and NMDA receptor antagonists for dementia
Substance Use Disorders: Pharmacotherapy for alcohol, opioid, and nicotine dependence
Special Populations: Pregnancy, geriatrics, pediatrics, and hepatic/renal impairment considerations
Drug Interactions and Adverse Effects: CYP450 interactions, QT prolongation, serotonin syndrome, and
neuroleptic malignant syndrome
Patient Education and Adherence: Strategies for promoting medication adherence and managing side effects
Clinical Decision-Making: Case-based scenarios integrating assessment, diagnosis, and pharmacologic
management
Evidence-Based Practice: Current guidelines and research in psychopharmacology
Legal and Ethical Considerations: Prescriptive authority, informed consent, and monitoring requirements
Exam Strategies: Test-taking tips and rationales for multiple-choice questions
Comprehensive Review: Integration of all topics across Exams 1, 2, and 3
Updates for 2026:
- Updated to reflect 2026/2027 DSM-5-TR and APA guidelines
- Incorporated latest FDA approvals and black box warnings
- Enhanced rationales with evidence-based references
- Added new case studies and clinical scenarios
- Revised to align with current WU curriculum and exam blueprint
Abstract:
This exam preparation document for NSG 552 Psychopharmacology provides a rigorous compilation of 200 actual
questions from Exams 1-3, with verified answers and detailed rationales. The content spans foundational
neuroscience, major drug classes, and clinical applications, ensuring comprehensive coverage of the course
syllabus. Each question is designed to test critical thinking and application of psychopharmacological principles in
Page 1
,patient care. The rationales explain correct and incorrect options, reinforcing learning and clarifying
misconceptions. Updated for the 2026/2027 academic year, this resource aligns with the latest evidence-based
practice and professional standards. It is an indispensable tool for nursing students aiming to excel in their
examinations and future clinical practice.
Keywords:
Psychopharmacology, NSG 552, Exam prep, Verified answers, Rationales, Nursing, 2026/2027, Guaranteed pass
Answer Format:
Each question is followed by the correct answer, a detailed rationale explaining why it is correct, and concise
explanations for why the other options are incorrect. Rationales include clinical pearls, drug mechanisms, and
relevant guidelines to enhance understanding and retention.
Compliance Checklist:
Aligned with 2026/2027 WU NSG 552 course objectives
Includes 200 actual exam questions with verified answers
Rationales provided for every answer option
Updated to reflect current psychopharmacology guidelines
Suitable for self-assessment and exam review
Content Area Overview:
Content Area Questions Key Topics Weight
Foundations of 1-20 Neurotransmission, receptor pharmacology, 10%
Psychopharmacology pharmacokinetics, pharmacodynamics
Antidepressants 21-50 SSRIs, SNRIs, TCAs, MAOIs, atypical 15%
antidepressants
Mood Stabilizers 51-70 Lithium, valproate, lamotrigine, monitoring 10%
Antipsychotics 71-100 First-generation, second-generation, 15%
clozapine, side effects
Anxiolytics and 101-120 Benzodiazepines, buspirone, z-drugs, 10%
Sedative-Hypnotics melatonin agonists
Stimulants and ADHD 121-140 Methylphenidate, amphetamines, 10%
Medications atomoxetine, alpha-2 agonists
Cognitive Enhancers 141-150 Cholinesterase inhibitors, NMDA 5%
antagonists
Substance Use Disorders 151-165 Alcohol, opioid, nicotine pharmacotherapy 8%
Special Populations 166-175 Pregnancy, geriatrics, pediatrics, organ 5%
impairment
Drug Interactions and Adverse 176-185 CYP450, QT prolongation, serotonin 5%
Effects syndrome, NMS
Patient Education and Adherence 186-190 Adherence strategies, side effect 2%
management
Clinical Decision-Making 191-195 Case-based scenarios, assessment, 3%
management
Evidence-Based Practice and 196-200 Guidelines, prescriptive authority, ethics 2%
Legal/Ethical
Page 2
,Q1. A patient with treatment-resistant depression is being considered for ketamine.
Which pharmacodynamic property best explains its rapid antidepressant effect?
A. Antagonism at the NMDA receptor with subsequent AMPA receptor upregulation
B. Inhibition of monoamine oxidase A and B
C. Blockade of serotonin reuptake and dual 5-HT2 antagonism
D. Allosteric modulation of GABA-A receptors
Correct Answer: A. Antagonism at the NMDA receptor with subsequent AMPA
receptor upregulation
Rationale: Ketamine's antidepressant effect is primarily attributed to noncompetitive
NMDA receptor antagonism, leading to enhanced AMPA receptor signaling and
downstream synaptogenesis. MAO inhibition, SSRI-like effects, and GABA modulation do
not produce the rapid, robust response characteristic of ketamine.
Why Wrong:
B - MAO inhibition increases monoamines but lacks the rapid synaptogenic
mechanisms of ketamine.
C - Serotonin reuptake blockade and 5-HT2 antagonism describe agents like
trazodone, which do not act within hours.
D - GABA-A modulation produces anxiolytic effects but is not associated with rapid
antidepressant efficacy.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 15
Q2. Which cytochrome P450 enzyme is primarily responsible for the metabolism of
aripiprazole, and what is the clinical implication for a patient with a poor CYP2D6
metabolizer phenotype?
A. CYP3A4; the drug will be metabolized faster, requiring dose escalation
B. CYP2D6; the drug will accumulate, increasing risk of extrapyramidal symptoms
C. CYP1A2; the drug will be less effective due to rapid clearance
D. CYP2C19; the drug will have reduced efficacy and require adjunctive therapy
Correct Answer: B. CYP2D6; the drug will accumulate, increasing risk of
extrapyramidal symptoms
Rationale: Aripiprazole is a substrate of CYP2D6 and CYP3A4. In poor metabolizers of
CYP2D6, aripiprazole exposure is increased, raising the risk of dose-dependent adverse
effects such as EPS and akathisia. Dose adjustment is recommended.
Why Wrong:
A - CYP3A4 is a minor pathway; poor CYP2D6 status causes accumulation, not faster
metabolism.
C - CYP1A2 is not a major pathway for aripiprazole.
D - CYP2C19 is not significantly involved in aripiprazole metabolism.
Page 3
, Reference: Stahl, S.M. (2026). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 6
Q3. A patient on fluoxetine is prescribed tramadol. What is the most serious potential
interaction and the mechanism?
A. Increased seizure risk due to lowered threshold
B. Serotonin syndrome due to excessive serotonin agonism
C. Hypertensive crisis due to monoamine oxidase inhibition
D. QT prolongation leading to torsades de pointes
Correct Answer: B. Serotonin syndrome due to excessive serotonin agonism
Rationale: Fluoxetine inhibits CYP2D6, which is needed to convert tramadol to its active
metabolite, but the combination also increases serotonin levels via both drugs, leading to
serotonin syndrome. Seizure risk is less specific and not the most serious interaction.
Why Wrong:
A - Both drugs can lower seizure threshold, but the more dangerous interaction is
serotonin syndrome.
C - Fluoxetine is not an MAOI; hypertensive crisis is more typical of MAOI-tyramine
interactions.
D - QT prolongation is possible but less specific to this combination.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 28
Q4. Which of the following best describes the mechanism of action of valproate in
mood stabilization?
A. Selective inhibition of voltage-gated sodium channels
B. Increase in brain GABA levels through inhibition of GABA transaminase
C. Blockade of dopamine D2 receptors in the mesolimbic pathway
D. Antagonism of glutamate at AMPA receptors
Correct Answer: B. Increase in brain GABA levels through inhibition of GABA
transaminase
Rationale: Valproate elevates GABA levels by inhibiting GABA transaminase and
enhancing GABA synthesis, which contributes to its antimanic and anticonvulsant effects.
Sodium channel blockade is more characteristic of carbamazepine and lamotrigine.
Why Wrong:
A - Sodium channel blockade is a mechanism of lamotrigine and carbamazepine, not
valproate.
C - D2 blockade is typical of antipsychotics.
D - AMPA antagonism is not a primary mechanism of valproate.
Reference: Stahl, S.M. (2026). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 11
Page 4
